McCune-Albright Syndrome: Growth Hormone and Prolactin Hypersecretion

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue , 2006, Pages 623-626

  Christoforidis, Athanasios ^a   Maniadaki, Ilianna ^a   Stanhope, Richard ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

bromocriptine; cabergoline; growth hormone excess; McCune Albright syndrome; octreotide; pegvisomant; prolactin hypersecretion; treatment

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PEGVISOMANT; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ALBRIGHT SYNDROME; ARTICLE; CLINICAL FEATURE; CRANIOFACIAL MALFORMATION; DRUG EFFICACY; GIGANTISM; GROWTH HORMONE RELEASE; HUMAN; HYPERCORTISOLISM; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; HYPERTHYROIDISM; INCIDENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRECOCIOUS PUBERTY; PROLACTIN RELEASE; SCREENING TEST; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT CONTRAINDICATION;

ADOLESCENT; FEMALE; FIBROUS DYSPLASIA, POLYOSTOTIC; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PITUITARY DISEASES; PITUITARY GLAND; PROLACTIN;

EID: 33745250543     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.S2.623     Document Type: Article

References (11)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E. Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-1695.
2. Scurry MT, Bicknell JM, Fajans SS. Polyostotic fibrous dysplasia and acromegaly. Arch Intern Med 1964; 114: 40-45.
3. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, LeRoith D, Cherman N, Bianco P, Wientroub S, Robey PG, Collins MT. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab 2002; 87: 5104-5112.
4. Lightner ES, Penny R, Frasier SD. Growth hormone excess and sexual precocity in polyostotic fibrous dysplasia (McCune-Albright syndrome): evidence for abnormal hypothalamic function. J Pediatr 1975; 87: 922-927.
5. Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J Clin Endocrinol Metab 1989; 68: 1148-1154.
6. de Pablo F, Eastman RC, Roth J, Gorden P. Plasma prolactin in acromegaly before and after treatment. J Clin Endocrinol Metab 1981; 53: 344-352.
7. Kovacs K, Horvath E, Thorner MO, Rogol AD. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch A Pathol Anat Histopathol 1984; 403: 77-86.
8. Mortensen A, Bojsen-Moller M, Rasmussen P. Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation. Two cases with a review of the literature. J Neurooncol 1989; 7: 25-29.
9. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994; 131: 229-234.
10. Geffner ME, Nagel RA, Dietrich RB, Kaplan SA. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome. J Pediatr 1987; 111: 740-743.
11. Trainer PJ. Lessons from 6 years of GH receptor antagonist therapy for acromegaly. J Endocrinol Invest 2003; 26 (Suppl): 44-52.